Care after pancreatic resection according to an algorithm for early detection and minimally invasive management of pancreatic fistula versus current practice (PORSCH-trial): design and rationale of a nationwide stepped-wedge cluster-randomized trial
Author:
Smits F. JasmijnORCID, , Henry Anne Claire, van Eijck Casper H., Besselink Marc G., Busch Olivier R., Arntz Mark, Bollen Thomas L., van Delden Otto M., van den Heuvel Daniel, van der Leij Christiaan, van Lienden Krijn P., Moelker Adriaan, Bonsing Bert A., Borel Rinkes Inne H. M., Bosscha Koop, van Dam R. M., Festen Sebastiaan, Groot Koerkamp B., van der Harst Erwin, de Hingh Ignace H., Kazemier Geert, Liem Mike, van der Kolk B. Marion, de Meijer Vincent E., Patijn Gijs A., Roos Daphne, Schreinemakers Jennifer M., Wit Fennie, van Werkhoven C. Henri, Molenaar I. Quintus, van Santvoort Hjalmar C.
Abstract
Abstract
Background
Pancreatic resection is a major abdominal operation with 50% risk of postoperative complications. A common complication is pancreatic fistula, which may have severe clinical consequences such as postoperative bleeding, organ failure and death. The objective of this study is to investigate whether implementation of an algorithm for early detection and minimally invasive management of pancreatic fistula may improve outcomes after pancreatic resection.
Methods
This is a nationwide stepped-wedge, cluster-randomized, superiority trial, designed in adherence to the Consolidated Standards of Reporting Trials (CONSORT) guidelines. During a period of 22 months, all Dutch centers performing pancreatic surgery will cross over in a randomized order from current practice to best practice according to the algorithm. This evidence-based and consensus-based algorithm will provide daily multilevel advice on the management of patients after pancreatic resection (i.e. indication for abdominal imaging, antibiotic treatment, percutaneous drainage and removal of abdominal drains). The algorithm is designed to aid early detection and minimally invasive step-up management of postoperative pancreatic fistula. Outcomes of current practice will be compared with outcomes after implementation of the algorithm. The primary outcome is a composite of major complications (i.e. post-pancreatectomy bleeding, new-onset organ failure and death) and will be measured in a sample size of at least 1600 patients undergoing pancreatic resection. Secondary endpoints include the individual components of the primary endpoint and other clinical outcomes, healthcare resource utilization and costs analysis. Follow up will be up to 90 days after pancreatic resection.
Discussion
It is hypothesized that a structured nationwide implementation of a dedicated algorithm for early detection and minimally invasive step-up management of postoperative pancreatic fistula will reduce the risk of major complications and death after pancreatic resection, as compared to current practice.
Trial registration
Netherlands Trial Register: NL 6671. Registered on 16 December 2017.
Funder
KWF Kankerbestrijding
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Medicine (miscellaneous)
Reference49 articles.
1. Conroy T, Hammel P, Hebbar M, Ben Abdelghani M, Wei AC, Raoul J-L, et al. FOLFIRINOX or gemcitabine as adjuvant therapy for pancreatic cancer. N Engl J Med. 2018;379:2395–406 [cited 2019 May 23]. Available from: http://www.nejm.org/doi/10.1056/NEJMoa1809775. 2. Harnoss JCJM, Ulrich AB, Harnoss JCJM, Diener MK, Büchler MW, Welsch T. Use and results of consensus definitions in pancreatic surgery: a systematic review. Surgery. 2014;155:47–57. 3. Williamsson C, Ansari D, Andersson R, Tingstedt B. Postoperative pancreatic fistula-impact on outcome, hospital cost and effects of centralization. HPB. 2017;19:436–42. 4. Watanabe Y, Nishihara K, Matsumoto S, Okayama T, Abe Y, Nakano T. Effect of postoperative major complications on prognosis after pancreatectomy for pancreatic cancer: a retrospective review. Surg Today. 2017;47:555–67. 5. Mackay TM, Smits FJ, Roos D, et al. The risk of not receiving adjuvant chemotherapy after resection of pancreatic ductal adenocarcinoma: a nationwide analysis. HPB (Oxford). 2019. https://doi.org/10.1016/j.hpb.2019.06.019 [published online ahead of print, 2019 Aug 19].
Cited by
25 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|